Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.40 |
| ▸ | MYC | P01106 | 1/20 | 0.40 |
| ▸ | MAX | P61244 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789683 | 0.92 | FFAR1 (0.49) | FFAR1KMT2AMEN1TDP1POLB | |
| SCHEMBL6788439 | 0.90 | FFAR1 (0.50) | FFAR1KMT2AMEN1TDP1POLB | |
| SCHEMBL6785809 | 0.90 | ALDH1A1 (0.48) | FFAR1KMT2AMEN1MCHR1POLB | |
| SCHEMBL6785812 | 0.90 | ALDH1A1 (0.48) | FFAR1KMT2AMEN1MCHR1POLB | |
| Benzamide SCHEMBL6798464 | 0.84 | PAX8 (0.47) | KMT2AMEN1POLBPAX8MAOA | |
| Benzamide SCHEMBL6786179 | 0.82 | PAX8 (0.47) | KMT2AMEN1TDP1POLBPAX8 | |
| SCHEMBL6791928 | 0.81 | DNM1 (0.48) | FFAR1KMT2AMEN1MCHR1POLB | |
| SCHEMBL6788428 | 0.81 | DNM1 (0.48) | FFAR1KMT2AMEN1MCHR1POLB | |
| SCHEMBL6790715 | 0.80 | MCHR1 (0.43) | FFAR1KMT2AMEN1MCHR1TDP1 | |
| SCHEMBL6790713 | 0.80 | MCHR1 (0.43) | FFAR1KMT2AMEN1MCHR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1192144-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | claimed |
| WO-2000076988-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | claimed |
| US-20040197268-A1 | Method of imaging amyloid deposits using substituted rhodanine derivatives | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1192144-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076988-A1 | RHODANINE DERIVATIVES AND THEIR USE IN INHIBITING AND IMAGING AMYLOIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040197268-A1 | Method of imaging amyloid deposits using substituted rhodanine derivatives | APP, PSEN1, PSEN2 | FFAR1 2567/4885KMT2A 4348/4885MEN1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.